Non-invasive collection
The patch is designed to collect interstitial fluid through a wearable, external application rather than relying on an additional invasive procedure.
Meet the innovation
Cervical cancer risk stratification, one patch at a time.
Curiva is developing diaPatch™, a non-invasive wearable diagnostic patch designed to support cervical cancer risk stratification and triage after an abnormal Pap smear, before colposcopy.
Cervical healthDiagnostic deviceChicago & Goshen, United States
Why it matters
Curiva identifies a gap in the clinical decision window after an abnormal Pap smear. Patients may face delays, anxiety and additional follow-up before receiving a clearer risk picture.
Its proposed approach is designed to give clinicians an adjunctive, non-invasive option that can support triage before colposcopy and reduce repeat visits and pathway friction.
The proposed solution
Curiva describes diaPatch™ as a wearable patch combining microneedles-mediated interstitial fluid sampling with a molecular assay for adjunctive cervical risk stratification and triage.
The patch is designed to collect interstitial fluid through a wearable, external application rather than relying on an additional invasive procedure.
Curiva’s target workflow is designed to support results in under 30 minutes during the clinical visit.
The intended use is to support cervical risk stratification after abnormal screening and before a colposcopy follow-up.
The companion ELLEApp™ is described as supporting result delivery and follow-up reminders.
Progress and potential
Curiva reports a strong intellectual-property focus, participation in the NSF I-Corps program, membership in innovation and accelerator communities, and active fundraising.
The company’s public materials describe diaPatch™ as under development. Regulatory requirements, clinical validation and product performance remain subject to further evaluation.
This profile summarizes Curiva’s public description of a proposed innovation. Participation in the award is not medical endorsement, clinical validation or regulatory approval.
Stand behind the idea
Your paid support backs this entry in the Women’s Health Community Award. Share Curiva’s profile with people working to improve earlier, more accessible cervical cancer care.
Community support point: 1
01 / Choose
Select your support quantity through the official award checkout. Each US$100 support payment adds one community support point; each point counts as one vote under the Official Rules.
02 / Confirm
Review the quantity, currency and final total before paying.
03 / Follow
Verified totals and the top-five updates are published during the award period.
Each US$100 support payment adds one community support point to your selected candidate. Each point counts as one vote under the Official Rules. The eligible candidate with the highest valid point total wins, subject to verification and the Official Rules.
Support payments are not donations, investments or credits redeemable for products or services.
What the primary winner receives
US$5,000–US$25,000
The cash prize starts at US$5,000, with announced increases potentially bringing it to US$25,000, plus a Strategic Discovery Process valued at US$4,800 and recognition through GO Vertical ICM’s network.
No. This profile is based on Curiva’s public description of a proposed innovation. Participation is not medical endorsement, clinical validation or regulatory approval.
December 31, 2026 at 11:59:59 p.m. EST. The winner is announced January 15, 2027 after verification.
Email info@goverticalicm.com with “Curiva,” your payment date and transaction reference. Never send card details or passwords.